Thanks to the combined work of AIM and the Alzheimer’s Association, the federal government has committed to a goal to prevent and effectively treat Alzheimer's disease by 2025. But achieving this goal requires a significant research commitment at the National Institutes of Health (NIH).
AIM has worked with the Alzheimer’s Association to propel the U.S. government to rise to this challenge, resulting in nearly tripling Alzheimer’s research funding in just five years - including a historic $414 million increase for Alzheimer’s research at the NIH in 2018. Today, funding for Alzheimer’s and dementia related research at the National Institutes of Health (NIH) is $1.8 billion.
Yet despite this progress, we still have much further to go.
That’s why AIM works to grow bipartisan support in Congress to secure additional federal research funding for the NIH. Leading experts say a greater investment is needed if we are to reach the first goal of the National Plan to Address Alzheimer's Disease - to prevent and effectively treat Alzheimer's by 2025. AIM, the Alzheimer’s Association, and our advocates are currently asking for Congress to approve a $425 million increase for the government’s 2019 budget.
|Food and Drug Administration Reauthorization Act of 2017 (FDARA) - Letter of Support|